26.04.2018
Biofrontera AG DE0006046113
DGAP-News: Biofrontera AG: Information on the prohibited purchase offer by Deutsche Balaton AG, Heidelberg, to the shareholders of Biofrontera AG and on the announcement of deltus 30. AG, Frankfurt am Main, pursuant to § 10 WpÜG dated 25 April 2018
DGAP-News: Biofrontera AG / Key word(s): Offer
Biofrontera AG: Information on the prohibited purchase offer by Deutsche
Balaton AG, Heidelberg, to the shareholders of Biofrontera AG and on the
announcement of deltus 30. AG, Frankfurt am Main, pursuant to § 10 WpÜG
dated 25 April 2018
26.04.2018 / 19:42
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Information on the prohibited purchase offer by Deutsche Balaton AG,
Heidelberg, to the shareholders of Biofrontera AG and on the announcement of
deltus 30. AG, Frankfurt am Main, pursuant to § 10 WpÜG dated 25 April 2018
Leverkusen, Germany, April 26, 2018 - Deutsche Balaton AG, Heidelberg,
published on March 16, 2018 pursuant to § 10 para. 1 and 3 WpÜG that it
decided to make a voluntary acquisition offer ("acquisition offer") for up
to 6,250,000 shares of Biofrontera AG. On April 25, 2018 it was announced
that the Federal Financial Supervisory Authority ("BaFin") had prohibited
the acquisition offer pursuant to § 15 WpÜG. Deutsche Balaton AG was
therefore not in a position to comply with the legal requirements with
regard to the required offer document, but rather violated legal provisions.
Since the acquisition offer was prohibited by BaFin, a renewed acquisition
offer by Deutsche Balaton AG is not permitted within one year pursuant to §
26 WpÜG. With this blocking period, the law aims to protect the interest of
the target company, in this case Biofrontera AG, to continue with
undisturbed operation of its business. The blocking period is intended to
prevent business activities from being affected repeatedly by individual
players due to the administrative and financial burden associated with an
acquisition offer for the target company.
The deltus 30th AG, Heidelberg, has published on April 25, 2018 according to
§ 10 para. 1 and 3 WpÜG that it has decided to make a voluntary acquisition
offer for up to 6,250,000 shares of Biofrontera AG. The announcement largely
corresponds to the above-mentioned announcement by Deutsche Balaton AG of 16
March 2018. deltus 30th AG is shortly to be renamed to Deutsche Balaton
Biotech AG. It is conceivable that an attempt is being made to circumvent
the blocking period for the protection of Biofrontera AG that was imposed
against Deutsche Balaton AG.
deltus 30th AG must now submit an offer document to BaFin within four weeks
after publication of their decision to make such an offer. Unless further
prohibition is imposed after evaluation by BaFin, the Management Board and
Supervisory Board of Biofrontera AG will comment on the Offer Document
pursuant to § 27 WpÜG. From today's perspective, no further comments by the
Management Board and/or the Supervisory Board of Biofrontera AG appear to be
necessary beyond the above explanations, which are made following various
requests for information.
-END-
Enquiries, please contact: +49 (0) 214 87 63 2 0
[email protected]
Biofrontera AG
Thomas Schaffer, Chief Financial Officer
IR UK: Seton Services +44(0) 20 7729 0805
Toni Vallen
IR and PR US: The Ruth Group +1 646-536-7035
IR: Tram Bui +1 508-280-6592
PR: Kirsten Thomas
About Biofrontera:
Biofrontera AG is an international biopharmaceutical company specializing in
the development and commercialization of a platform of pharmaceutical
products for the treatment of dermatological conditions and diseases caused
primarily by exposure to sunlight that results in sun damage to the skin.
Biofrontera's approved products focus on the treatment in the U.S. and
Europe of actinic keratoses, which are skin lesions that can sometimes lead
to skin cancer, as well as the treatment of certain forms of basal cell
carcinoma in the European Union. American Depositary Shares representing
Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under
the symbol "BFRA", and Biofrontera's ordinary shares are listed in the
Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also
available at www.biofrontera.com.
Forward Looking Statements:
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 regarding
the public offering and the intended use of proceeds from the offering.
These statements may be identified by the use of forward-looking words such
as "anticipate," "believe," "forecast," "estimate" and "intend," among
others. Such forward-looking statements are based on the currently held
beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance, or
achievements of the Company, or industry results, to differ materially from
the results, financial condition, performance or achievements expressed or
implied by such forward-looking statements. These risks, uncertainties and
other factors are set forth in the Registration Statement on Form F-1 filed
with the SEC, including in the section "Risk Factors," and in future reports
filed with the SEC. Given these risks, uncertainties and other factors,
prospective investors are cautioned not to place undue reliance on these
forward-looking statements. The Company does not undertake an obligation to
update or revise any forward-looking statement.
---------------------------------------------------------------------------
26.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service
---------------------------------------------------------------------------
680047 26.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biofrontera AG ISIN: DE0006046113 können Sie bei EQS abrufen
Biotechnologie , 604611 , B8F , XETR:B8F